Dear members and other friends of NSGO,

At the turn of the year, it is customary to take a look into the year passed. One of the most discussed topics of 2018, in general, has been the realization of the plastic crisis we (and the Earth) are facing. In gynecologic oncology, the results of two clinical trials have been dominating discussions. First, from the SOLO trial we have learned, the PARP-inhibition truly has a significant impact in ovarian cancer treatment. The original discovery of the BRCA genes 25 years ago has evolved into something that can be considered as a game changer for a great number of ovarian cancer patients. Secondly, the results from the LACC trial, looking at the difference between open and minimally invasive surgical approach in cervical cancer, challenge the minimally invasive approach and call for a re-evaluation of treatment practices.

In my view, the field of gynecologic oncology has never been as interesting as it is now. Therefore, I truly must congratulate the local organizers of the NSGO Annual Meeting 2019 (Copenhagen 27-29 March) for suggesting such an attractive theme as “Advances in the Management of Gynaecological cancer patients” for this conference. The program structure, with almost 20 European experts as speakers and several panels with Nordic and European experts guarantee lively discussions and opportunities to ventilate the impact of these, as also other studies, on our treatment practices.

Take a look at the program, I hope you want to participate.

Looking forward seeing you in Copenhagen!

Annika Auranen, President of NSGO

NSGO Annual Meeting
March 27-29, 2019
Advances in the Management of Gynaecological Cancer Patients
Radisson Blu Scandinavia Hotel – Copenhagen
On-line registration is now open

NSGO GOLD SPONSORS 2018

AstraZeneca  Clovis Oncology  Intuitive Surgical
Roche  Tesaro
Dear NSGO friends,

In 2018 NSGO-CTU had considerable achievements:

We are successfully conducting the following NSGO sponsored or led trials:

Endometrial Cancer
- EN1 / FANDANGO: recruitment is completed, and data is being cleaned.
- EN2: is completing recruitment and we need 6 more patients.
- EN3 / PALEO: recruitment is completed, and data is being cleaned
- EN6: expected to start in early Q3 2019

Ovarian Cancer
- AVANOVA1: completed & manuscript will be submitted in March 2019
- AVANOVA2: completed and results to be presented at ASCO 2019
- OV-UMB1: ongoing
- OV-42: To be started

Cervical Cancer
- MaRuC: to be started

NSGO-CTU is now one of the leading trial groups within ENGOT and within GCIG and all this will not be possible without your support, great work of NSGO office staff and without great international collaboration through ENGOT & GCIG.

I would like to thank you for all your support. I also want to thank our collaborators (GSO, GCP-Enhederne, Signifikans, Ovacure and the collaborating pharma partners).

I am looking forward to see you at our 2019 investigator meetings in Copenhagen: 28th of March during NSGO Annual meeting 2019 and the stand-alone fall meeting on 28th – 29th November.

Best regards, Mansoor
The NSGO Surgery Group

First I want to thank you all for your attendance at the annual meeting in Lund!

The main activities in the surgery group are planned to coincide with the NSGO annual meeting and I am looking forward seeing you all in Copenhagen in late March this year!

If you have any proposals for the agenda of the meeting in Copenhagen, please let me know in due time.

ERAS

In Lund, Kristina Lindeman, Oslo informed about the ERAS survey and the advantages by patterns of uniform perioperative care on European level. More of the representatives from the Nordic centres expressed their interest in a future collaboration regarding the perioperative care, and hopefully we will get an update at the meeting in Copenhagen about the progress of the project.

NSGO survey

The NSGO survey examining the staging of cervical cancer in the Nordic countries has now been published in Acta:

*Cervical cancer staging, pretreatment planning, and surgical treatment in the Nordic countries- Survey from the Surgical Subcommittee of the Nordic Society of Gynecological Oncology.*


The next survey from the Surgery Group is in preparation and deals with the management of rare gynecologic tumors in the Nordic centers. We informed about this survey in Lund, but the survey hasn’t been initiated yet.

HIPEC in ovarian cancer

The Dutch study "Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer" published in New England Journal of Medicine by van Driel, WJ et al. has initiated an European protocol joined by more Nordic countries. I am sure that we will hear more about this protocol in Copenhagen and hopefully, some members from the attending centers will update the surgery group at the meeting.

Cervical cancer and minimal invasive surgery

The risk of recurrence after minimal invasive surgery in cervical cancer has been much debated in 2018 and minimally invasive surgery in early stage cervical cancer, the Danish experience - and the Swedish experience was a topic of the Kolstad-Tropé meeting in Oslo in December. I am sure that this will be discussed in Copenhagen too, and let this be an appetizer for joining the surgery group meeting in Copenhagen!

*I am looking forward seeing you all in Copenhagen!*

*Jan Blaakær*

*Odense, 4th of January, 2019*
At the NSGO Strategic Meeting 29 September 2018 a Media Working Group was established. It is the NSGO Board’s wish, that NSGO website will provide all NSGO members and others with interest in the work of NSGO and NSGO-CTU with relevant information in a user friendly and intuitive way. The purpose of the Media Working Group is therefore to modernize the NSGO website and use more of the features that are available in the new WordPress website system. The Media Working Group will have their first meeting on 28 March 2019 during NSGO Annual Meeting.

Members of the Media Working Group are; Katrin Kristjansdottir (Iceland), Jan-Erik Palmgren (Finland), Gabriel Lindahl (Sweden), Elisabeth Berge Nilsen (Norway), Claus Högdahl (Denmark) and Administrative leader/webmaster Solveig Ristinge (NSGO Office).

Good ideas and input from all readers of the NSGO newsletter are welcome and can be sent to the NSGO Office: solveig.elisabeth.ulstrup.ristinge@regionh.dk.

Kind regards, Solveig Ristinge.

A Final Word from the Editor

Dear NSGO members and friends,

As the saying goes; all good things must come to an end.

Leaving another highly interesting Investigator Meeting in Copenhagen I take the opportunity to use the hours travelling writing my last editorial in (probably) our last PDF-version of the NSGO newsletter. Part of the new NSGO Media Working Group’s assignment is to find more modern strategies to communicate with our members and sponsors, abandoning the old fashioned e-mailing of PDFs. The discussion concerning the new format is however at a very early stage, but will hopefully be ready and presented to you by spring next year.

Once again the Investigator Meeting showed the strength of NSGO as a collaborating workgroup where we in the Scandinavian countries have 20 open or ongoing trials and where NSGO is sponsor in numerous trials and by that is one of the major trial groups in Europe. It is also comforting to realize that we actually have several ongoing trials not only in ovarian cancer, but also in endometrial and cervical cancer. This gives the opportunity to more patients with advanced disease and poor prognosis to participate in trials with new targeted therapies.

But, travelling (by train) through the gloomy landscape in the dark and snowless southern parts of Sweden I come to think of the upcoming Climate Change Conference in Polish Katowice in December. I have the notion that we all somehow must contribute to reduce our ecological footprint and maybe it is time even for our organisation to add to our bylaws that we strive to work in a sustainable fashion (as a secondary endpoint 😊 - the primary must always be, in accordance with our bylaws paragraph 2.1.1, “to be a Nordic platform for individual professionals dedicated to the care of women with gynaecological cancer”).

Well met in Copenhagen 2019!

Gabriel Lindahl, Linköping